N/A
N=89
TENS Treatment for Bedwetting
Nocturnal Enuresis · Bed Wetting
Bottom Line
View on ClinicalTrials.gov: NCT04313192 ↗Enrolled (actual)
89
Serious AEs
0.0%
Results posted
Apr 2026
Primary outcome: Primary: Percentage of Wet Nights — -0.104790479; -0.099141959; -0.111602158 %change wet nights
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- pulse rate of 2 Hz (Device); pulse rate of 10 Hz (Device); pulse rate of 150 Hz (Device)
- Age
- Pediatric, Adult · 5+ yrs
- Sex
- All
- Sponsor
- Albany Medical College
- Primary completion
- Dec 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Wet Nights |
-0.104790479; -0.099141959; -0.111602158 | — |
| SECONDARY Severity of Wet Nights |
-0.422916667; -0.1484; -0.1935 | — |
| SECONDARY Pediatric Incontinence Questionnaire (PIN-Q) |
0; -0.538461538; -2.541666667 | — |
Summary
Children referred to pediatric urology clinic for primary nocturnal enuresis will be screened for enrollment. Patients who fail will next be offered therapy with a bedwetting alarm device or a TENS unit as an alternative, and those who chose TENS therapy will be included in the study.The patients will be randomized into three groups of 30 patients each. Group 1 will be the long frequency set at 2 Hz (hertz). Group 2 will be the moderate frequency set at 10 Hz. Group 3 will be the short frequency set 150 Hz. The patients will be provided with a TENS unit and electrode pads and caretakers instructed on how to use the apparatus.
The child's TENS unit will be set at a frequency determined by randomization, pulse width of 260 seconds, and an intensity to be determined in the office based upon when the child feels sensitive to the TENS unit. The child will be randomized and will place the electrodes along the posterior tibial nerve on the medial ankle each night before bed time for 15 minutes for a total of 30 days. Diaries including nighttime incontinence episodes and a "wet sheet" scale (dry, damp, wet, soaked) will be recorded, along with any adverse reactions to the TENS unit. Patients will be followed up after one month of TENS with evaluation including the Pediatric Urinary Incontinence Questionnaire, a validated tool for measuring quality of life in children with bladder dysfunction; this questionnaire will be filled out prior to starting TENS treatment in order to compare the effect of treatment on QOL. The data will be collected at different time points (baseline and after 1 month of treatment) for each group by itself and the groups compared against each other using statistical analysis.
Eligibility Criteria
Inclusion Criteria
- Presenting with nocturnal enuresis (more than 1x a week)
- Failed Behavioral modification treatment (limiting evening drinking, double voiding prior to bedtime, bowel habits, social anxiety factors)
- Ability to provide informed consent and assent and complete study requirements
Exclusion Criteria
- Patients who have previously tried pharmacologic treatment for nocturnal enuresis, neuromodulation or other alternative therapy for urologic disorders within the past 30 days
- Daytime incontinence symptoms
- Known "high volume" voiders (determined from history)
- Bedwetting episodes on the average of less than two times per week,
- Medications predisposing to incontinence (eg, Lithium for bipolar disorder)
- Other known voiding or neurologic disorders (eg, overactive bladder, myelomeningocele, interstitial cystitis, etc)
- Secondary etiologies for nocturnal enuresis (eg, cystitis, obstructive sleep apnea, urinary fistulae, heart disease)
- Any contraindications to usage of a TENS unit (pacemaker or other implantable device, lymphedema, pregnancy, malignancy,bleeding or clotting disorders, unhealthy tissue, seizure disorders, impaired cognition)
- Any history of heart disease or complications
Data sourced from ClinicalTrials.gov (NCT04313192). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.